Harvard Bioscience, Inc. (NASDAQ:HBIO) Sees Large Decrease in Short Interest

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 374,100 shares, a decrease of 6.2% from the October 31st total of 398,900 shares. Based on an average daily volume of 136,800 shares, the short-interest ratio is presently 2.7 days.

Harvard Bioscience Trading Up 1.8 %

NASDAQ HBIO opened at $2.24 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. Harvard Bioscience has a fifty-two week low of $1.99 and a fifty-two week high of $5.56. The stock has a market cap of $97.71 million, a P/E ratio of -6.79 and a beta of 1.27. The stock has a 50 day simple moving average of $2.38 and a two-hundred day simple moving average of $2.77.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in shares of Harvard Bioscience during the 3rd quarter valued at about $30,000. Allspring Global Investments Holdings LLC bought a new stake in Harvard Bioscience during the 2nd quarter valued at approximately $31,000. SG Americas Securities LLC purchased a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $36,000. Avior Wealth Management LLC raised its position in shares of Harvard Bioscience by 1,118.1% in the 3rd quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 13,373 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Harvard Bioscience in the 2nd quarter valued at approximately $40,000. 80.87% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.